Skip to main content

Select Drug Profiles

FDA Approvals
Imbruvica (Ibrutinib) Receives Expanded Indication, in Combination with Rituximab, as First-Line Treatment for Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Mayzent (Siponimod) Approved for Relapsing Forms of Multiple Sclerosis, Including Active Secondary Progressive Disease
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Pemazyre (Pemigatinib) First Targeted Therapy FDA Approved for Cholangio­carcinoma with FGFR2 Biomarker
Loretta Fala
Read More
FDA Approvals
Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma
Loretta Fala
Read More
FDA Approvals
Trodelvy (Sacituzumab Govitecan-hziy) a New Targeted Therapy for Patients with Metastatic Triple-Negative Breast Cancer
Loretta Fala
Read More
FDA Approvals
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Loretta Fala
Read More
FDA Approvals
FDA Approvals of Brand-Name Prescription Drugs, January 1, 2019, Through June 15, 2020
Read More
Leukemia, Lymphoma, Oncology
Long-Term Data Support Use of Acalabrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Chase Doyle
Chase Doyle
Read More
Maintenance Avelumab New Standard of Care for Advanced Bladder Cancer
Phoebe Starr
Phoebe Starr
Read More
Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer
Wayne Kuznar
Wayne Kuznar
Read More
Page 31 of 244
Results 301 - 310 of 2438